{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":41,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":41,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"c3179db2e965","filters":{"venue":"Immuno-Oncology Technology"}},"results":[{"id":"W4405375041","doi":"10.1016/j.iotech.2024.100746","title":"117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Medical physics; Internal medicine; Cancer; Immunotherapy; Biology","authors":[{"name":"Andreas Pircher","is_ca":false},{"name":"Szabolcs Soter","is_ca":false},{"name":"Michael A. W. Eaton","is_ca":false},{"name":"G. Galffy","is_ca":false},{"name":"D. Kowalski","is_ca":false},{"name":"Atsushi Hata","is_ca":false},{"name":"Abdhiel Bustamante-Navarrete","is_ca":false},{"name":"Nikolaj Frost","is_ca":false},{"name":"E. Levchenko","is_ca":false},{"name":"Mariana P. Monteiro","is_ca":false},{"name":"Anoop Haridass","is_ca":false},{"name":"M. Bouchard","is_ca":true},{"name":"M.V. Bluthgen","is_ca":false},{"name":"M-J. Ahn","is_ca":false},{"name":"B.G.M. Hughes","is_ca":false},{"name":"Amy C. Durham","is_ca":false},{"name":"Yiquan Xu","is_ca":false},{"name":"Ayman Samkari","is_ca":false},{"name":"A. Song","is_ca":false},{"name":"Salma K. Jabbour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0171213817156222,"gpt":0.3587965159867576,"spread":0.3416751342711354,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009073637,0.0007982142,0.002196153,0.0008850752,0.0005945308,0.0001022652,0.0006845262,0.0007238592,0.0004229599],"category_scores_gemma":[0.00005175178,0.0004772136,0.0004440816,0.001258321,0.0007793105,0.0001441175,0.0002223308,0.001114964,0.00001466066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002452344,"about_ca_system_score_gemma":0.001979605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001120146,"about_ca_topic_score_gemma":0.001005899,"domain_scores_codex":[0.9959817,0.000269329,0.001037048,0.001250365,0.000360953,0.001100594],"domain_scores_gemma":[0.9963273,0.001253782,0.0004380088,0.001467134,0.0003658278,0.0001479165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9305453,0.01022023,0.005467124,0.0007511221,0.01578308,0.00162709,0.005812145,0.00005234269,0.008318468,0.001101473,0.005463334,0.01485834],"study_design_scores_gemma":[0.9280694,0.01757894,0.000188566,0.000425388,0.005942056,0.0003926281,0.001689438,0.002248736,0.009560136,0.000062017,0.03324534,0.0005973654],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9250619,0.04066495,0.001881964,0.01076169,0.001436719,0.01845328,0.00007131457,0.0007497063,0.0009184049],"genre_scores_gemma":[0.9683782,0.003934121,0.00046155,0.0005331371,0.0003274337,0.02219075,0.00007013683,0.0001960381,0.003908657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0433162,"threshold_uncertainty_score":0.999768,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","authors":[{"name":"Natasha B. Leighl","is_ca":true},{"name":"Luis Paz‐Ares","is_ca":false},{"name":"Delvys Rodríguez‐Abreu","is_ca":false},{"name":"Rina Hui","is_ca":false},{"name":"Sofia Baka","is_ca":false},{"name":"Frédéric Bigot","is_ca":false},{"name":"Makoto Nishio","is_ca":false},{"name":"Alexey Smolin","is_ca":false},{"name":"S. Ahmed","is_ca":false},{"name":"Adam J. Schoenfeld","is_ca":false},{"name":"S. Daher","is_ca":false},{"name":"Diego Cortinovis","is_ca":false},{"name":"V.P. Di Noia","is_ca":false},{"name":"Helena Linardou","is_ca":false},{"name":"Justin F. Gainor","is_ca":false},{"name":"Chinyere E. Okpara","is_ca":false},{"name":"Xuan Deng","is_ca":false},{"name":"Debra Kush","is_ca":false},{"name":"Andrew Song","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04270142033337985,"gpt":0.3679328438520774,"spread":0.3252314235186975,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006305632,0.0005054331,0.001425831,0.0009695114,0.00025716,0.00002048339,0.0003580751,0.0005283433,0.00007846915],"category_scores_gemma":[0.0001043985,0.0004520815,0.0001922571,0.001004096,0.0005643222,0.00008458404,0.0001402249,0.0005437829,0.000003824981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000536883,"about_ca_system_score_gemma":0.0007845883,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002478348,"about_ca_topic_score_gemma":0.0002638332,"domain_scores_codex":[0.997198,0.0001002268,0.0008653952,0.0007743707,0.0002653164,0.0007967271],"domain_scores_gemma":[0.9977129,0.0006392341,0.0006901867,0.0006811291,0.0001951902,0.00008140013],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2905379,0.005673955,0.007625679,0.0009205259,0.005150198,0.000357731,0.01799028,0.00002999629,0.3854115,0.0001112738,0.002667592,0.2835234],"study_design_scores_gemma":[0.6193648,0.09214257,0.00325797,0.000783885,0.001804531,0.0001676679,0.04153956,0.002983197,0.2247319,0.0001125282,0.01197784,0.001133568],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9879132,0.003296883,0.0001138127,0.001940431,0.0008355594,0.005178561,0.00005466001,0.0003898257,0.0002770488],"genre_scores_gemma":[0.9949264,0.0008602545,0.0007256438,0.0003061582,0.0001030817,0.002622692,0.00005046135,0.0001067511,0.0002985484],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3288269,"threshold_uncertainty_score":0.9997931,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","authors":[{"name":"Margarita Majem","is_ca":false},{"name":"M.C. Garassino","is_ca":false},{"name":"G. Zhao","is_ca":false},{"name":"B. Mennecier","is_ca":false},{"name":"C. Grohe","is_ca":false},{"name":"Namiko Ikeda","is_ca":false},{"name":"J. Bosch-Barrera","is_ca":false},{"name":"Roger Keresztes","is_ca":false},{"name":"Yinjun Lou","is_ca":false},{"name":"H. Chen","is_ca":false},{"name":"Debasis Das","is_ca":false},{"name":"Sandra Keller","is_ca":false},{"name":"Ayman Samkari","is_ca":false},{"name":"Jonathan Spicer","is_ca":true},{"name":"H. Wakelee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008401937325614091,"gpt":0.2975276717874244,"spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004759711,0.000584134,0.001404806,0.001256375,0.0001135984,0.00003782164,0.0006123501,0.001284007,0.001206479],"category_scores_gemma":[0.00003944309,0.0005255289,0.0003409308,0.0016453,0.0009833997,0.0001506948,0.0002211781,0.001289368,0.00005802807],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001795996,"about_ca_system_score_gemma":0.002252915,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001725722,"about_ca_topic_score_gemma":0.0006275121,"domain_scores_codex":[0.9966955,0.0001149427,0.001058741,0.0009381128,0.0002621849,0.0009305739],"domain_scores_gemma":[0.9983726,0.0001275614,0.0002781515,0.0009291123,0.0002011029,0.00009143542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01550478,0.0007516054,0.01837312,0.000862967,0.001473871,0.001027841,0.007360711,0.00003523428,0.8715518,0.0009370385,0.001689555,0.08043148],"study_design_scores_gemma":[0.06894076,0.006397613,0.02492078,0.002640096,0.0006727506,0.0007967437,0.005767145,0.005272923,0.6718852,0.0002252823,0.2106531,0.001827624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9538506,0.03138736,0.0003714415,0.007449036,0.0009803334,0.001642549,0.00007230524,0.0003907369,0.003855617],"genre_scores_gemma":[0.9826371,0.01058496,0.001409112,0.0009315917,0.0001248393,0.0005689145,0.0000335995,0.0001402254,0.003569669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2089635,"threshold_uncertainty_score":0.9997196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401502464","doi":"10.1016/j.iotech.2024.100726","title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alethia Biotherapeutics (Canada)","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; European Commission; Helsingin Yliopisto; Les Laboratories Pierre Fabre; Syöpäsäätiö; Novo Nordisk; Sanofi","keywords":"Oncolytic adenovirus; Oncolytic virus; Metastatic melanoma; Melanoma; Mucosal melanoma; Medicine; Tilt (camera); Cancer research; Tumor cells","authors":[{"name":"Tine Monberg","is_ca":false},{"name":"Tatiana V. Kudling","is_ca":false},{"name":"Benedetta Albieri","is_ca":false},{"name":"Santeri A. Pakola","is_ca":false},{"name":"Eva Ellebæk","is_ca":false},{"name":"Marco Donia","is_ca":false},{"name":"Rikke Løvendahl Eefsen","is_ca":false},{"name":"Christian von Buchwald","is_ca":false},{"name":"Claudia Kistler","is_ca":true},{"name":"João M. Santos","is_ca":true},{"name":"James H.A. Clubb","is_ca":true},{"name":"L. Haybout","is_ca":true},{"name":"Marie Christine Wulff Westergaard","is_ca":false},{"name":"Dafne C.A. Quixabeira","is_ca":true},{"name":"Elise Jirovec","is_ca":false},{"name":"Riikka Havunen","is_ca":true},{"name":"S. Sorsa","is_ca":true},{"name":"Víctor Cervera-Carrascón","is_ca":true},{"name":"A. Hemminki","is_ca":true},{"name":"Inge Marie Svane","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01077100026985764,"gpt":0.2736602485286825,"spread":0.2628892482588249,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000405177,0.0004379815,0.0005774685,0.0006005648,0.0001252221,0.00005868574,0.0002858569,0.0002824372,0.00004885834],"category_scores_gemma":[0.00007140166,0.0003298948,0.00006188672,0.0006325212,0.0008062567,0.00001534051,0.000188706,0.0003118815,0.00003051974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005721496,"about_ca_system_score_gemma":0.001220937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001110073,"about_ca_topic_score_gemma":0.001971857,"domain_scores_codex":[0.997381,0.0004277932,0.0004509281,0.0008152972,0.0001873508,0.0007376428],"domain_scores_gemma":[0.9987957,0.0002320768,0.0001153352,0.0006684213,0.00009447585,0.00009401353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06511795,0.0004462822,0.002933565,0.00005786876,0.0006519245,0.004889259,0.0004413857,0.00005056433,0.9026536,0.00006048248,0.00004962043,0.02264748],"study_design_scores_gemma":[0.01509913,0.2096134,0.001484654,0.0002881472,0.0002255379,0.008195328,0.002215822,0.0009808472,0.7334855,0.0003149889,0.02705749,0.00103909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9869729,0.01015326,0.00006770542,0.001461159,0.00007000149,0.0009379274,0.00005021141,0.0001213253,0.0001655259],"genre_scores_gemma":[0.996284,0.000330126,0.00173153,0.0002439484,0.00002052011,0.001119707,0.00004159641,0.00008222458,0.0001463552],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2091672,"threshold_uncertainty_score":0.9999153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","authors":[{"name":"Solange Peters","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false},{"name":"Alexander Luft","is_ca":false},{"name":"J.A. Alatorre Alexander","is_ca":false},{"name":"Sarayut Lucien Geater","is_ca":false},{"name":"К. К. Лактионов","is_ca":false},{"name":"Dmytro Trukhin","is_ca":false},{"name":"Seung‐Whan Kim","is_ca":false},{"name":"G. Ursol","is_ca":false},{"name":"Maen Hussein","is_ca":false},{"name":"F. Lim","is_ca":false},{"name":"Cheng‐Ta Yang","is_ca":false},{"name":"L.H. Araujo","is_ca":false},{"name":"H. Saito","is_ca":false},{"name":"Niels Reinmuth","is_ca":false},{"name":"Leah Szadkowski","is_ca":true},{"name":"C. Lowery","is_ca":false},{"name":"Edward B. Garon","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Melissa L. Johnson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02537940517961945,"gpt":0.3139009496148696,"spread":0.2885215444352501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001612457,0.0006060202,0.00141911,0.0008981072,0.0003158675,0.00003941052,0.001049347,0.0004411705,0.001198363],"category_scores_gemma":[0.0003318563,0.0004645087,0.0003152696,0.002438789,0.0007602196,0.0001310002,0.0003483199,0.001155668,0.000456615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008040701,"about_ca_system_score_gemma":0.0004852102,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002571119,"about_ca_topic_score_gemma":0.006078797,"domain_scores_codex":[0.995767,0.000464225,0.001207721,0.0009952752,0.0004938462,0.001071913],"domain_scores_gemma":[0.9968348,0.0008267693,0.0003917206,0.001722869,0.0001420187,0.00008184253],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05302535,0.01150042,0.2505793,0.0001410315,0.01033231,0.006113156,0.006473698,0.000136677,0.1220899,0.001867827,0.02249443,0.5152459],"study_design_scores_gemma":[0.1432552,0.01235464,0.4292913,0.0004586065,0.001171693,0.0006990294,0.01872679,0.0008439933,0.008427606,0.009391535,0.3734807,0.001898869],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9509711,0.003616202,0.00004327789,0.0403178,0.001371529,0.002250215,0.00006944696,0.0008400572,0.0005204048],"genre_scores_gemma":[0.9919168,0.004618244,0.0003033781,0.001692399,0.0001773728,0.0004477862,0.0001884374,0.0001338703,0.0005217447],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.513347,"threshold_uncertainty_score":0.9997807,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480868","doi":"10.1016/j.iotech.2023.100606","title":"134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Chugai Pharmaceutical; Incyte; Sierra Oncology; Da Volterra; Ipsen; Eisai; Bristol-Myers Squibb; AstraZeneca; Carrick Therapeutics; Pfizer; Dr. Falk Pharma; ViiV Healthcare","keywords":"Tolerability; Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Pharmacology; Clinical trial","authors":[{"name":"David J. Pinato","is_ca":false},{"name":"Udai Banerji","is_ca":false},{"name":"Sylvie Rottey","is_ca":false},{"name":"Katriina Peltola","is_ca":false},{"name":"Jeffrey Yachnin","is_ca":false},{"name":"Rebecca Kristeleit","is_ca":false},{"name":"Martin Gutierrez","is_ca":false},{"name":"Stefan N. Symeonides","is_ca":false},{"name":"Nina Louise Jebsen","is_ca":false},{"name":"M. Hoejgaard","is_ca":false},{"name":"William J. Edenfield","is_ca":false},{"name":"Knut B. Smeland","is_ca":false},{"name":"Aglaia Schiza","is_ca":false},{"name":"Lars Ny","is_ca":false},{"name":"V. Ebiana","is_ca":false},{"name":"Jeannie Daniel","is_ca":false},{"name":"Jennifer Pulini","is_ca":false},{"name":"Ruth Plummer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04229348806635307,"gpt":0.3719076108827646,"spread":0.3296141228164115,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001881926,0.0002500276,0.001189688,0.0005188298,0.0002671087,0.000005858295,0.0005357577,0.0003421284,0.00003529602],"category_scores_gemma":[0.001974203,0.0001589668,0.00009218289,0.00206508,0.001464526,0.0000575979,0.0008144485,0.001133853,0.00001538231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003662565,"about_ca_system_score_gemma":0.0006692944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001625408,"about_ca_topic_score_gemma":0.0006193146,"domain_scores_codex":[0.9970971,0.0005526258,0.000916168,0.0005133659,0.0002342726,0.0006864879],"domain_scores_gemma":[0.9976512,0.0008880445,0.0002372822,0.0009804043,0.0001793369,0.00006378406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004831895,0.003279988,0.7783114,0.0001308926,0.000418385,0.0004466828,0.005665003,0.00001988998,0.1382902,0.000507989,0.0001044387,0.06799319],"study_design_scores_gemma":[0.02674679,0.01580385,0.8778682,0.0002920152,0.0003717481,0.0005882822,0.02711055,0.001344609,0.04428941,0.001831214,0.003331534,0.0004217736],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896411,0.0004360185,0.00001970364,0.006397722,0.0002315331,0.002335455,0.000007460004,0.0001795411,0.0007515094],"genre_scores_gemma":[0.9982367,0.0003404033,0.0001673691,0.0001396978,0.00003436988,0.0008312867,0.000004920783,0.00002837148,0.0002168655],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09955678,"threshold_uncertainty_score":0.6482478,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","authors":[{"name":"Matteo Simonelli","is_ca":false},{"name":"M.O. Butler","is_ca":true},{"name":"P.A. Ascierto","is_ca":false},{"name":"G.V. Long","is_ca":false},{"name":"E. Calvo","is_ca":false},{"name":"C. Gebhardt","is_ca":false},{"name":"J.J. Grob","is_ca":false},{"name":"A.M. Haydon","is_ca":false},{"name":"G. Quéreux","is_ca":false},{"name":"J. Walker","is_ca":false},{"name":"Manoj Kumar","is_ca":false},{"name":"D. Chakraborty","is_ca":false},{"name":"Xu Zhu","is_ca":false},{"name":"Ignacio Melero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008657859952414042,"gpt":0.2774406519264998,"spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000931239,0.0003755923,0.001661643,0.0009428537,0.0001742488,0.00001788176,0.0005633139,0.0004105035,0.0001457919],"category_scores_gemma":[0.0001428035,0.0002049609,0.0002466351,0.003740381,0.00131304,0.0001234623,0.0001875949,0.0008224278,0.000003645033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008154055,"about_ca_system_score_gemma":0.0006102847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001652289,"about_ca_topic_score_gemma":0.006222238,"domain_scores_codex":[0.9969364,0.0005634896,0.0009990287,0.0006499258,0.0003957578,0.0004553576],"domain_scores_gemma":[0.9977614,0.0005837354,0.0004342826,0.00101209,0.0001805073,0.00002801734],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5114074,0.01322886,0.3235366,0.00007118074,0.01086411,0.0003586503,0.007967453,0.0002041764,0.005384441,0.0003339698,0.0002975323,0.1263456],"study_design_scores_gemma":[0.8140933,0.02113009,0.1456607,0.0005452395,0.003632281,0.00005179162,0.006122132,0.001365196,0.002845817,0.0002662761,0.003812307,0.0004749108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896531,0.003045817,0.0000791643,0.003260729,0.0003952253,0.003187416,0.00005399101,0.0001197138,0.0002048525],"genre_scores_gemma":[0.9985675,0.0002742041,0.0001344923,0.0001455838,0.00001990128,0.0005736843,0.00008330806,0.00003792135,0.0001633964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3026859,"threshold_uncertainty_score":0.8358063,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","authors":[{"name":"Martin Reck","is_ca":false},{"name":"Ernest Nadal","is_ca":false},{"name":"Nicolas Girard","is_ca":false},{"name":"A.R.R. Filippi","is_ca":false},{"name":"L.W. Martin","is_ca":false},{"name":"C.M. Gay","is_ca":false},{"name":"Cordula Petersen","is_ca":false},{"name":"Daniel P. Gale","is_ca":false},{"name":"H.R. Bridge","is_ca":false},{"name":"Naomi Donner","is_ca":false},{"name":"N.E. Georgoulia","is_ca":false},{"name":"Jonathan Spicer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02619642708077443,"gpt":0.3546546211225938,"spread":0.3284581940418194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000928574,0.0003749014,0.001409794,0.0008827444,0.0002168474,0.00001717647,0.0002568831,0.0003451153,0.0002706915],"category_scores_gemma":[0.0004911989,0.0002712495,0.00004537799,0.001930451,0.0007768781,0.0001257845,0.0001979359,0.0005873294,0.000002758647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002005076,"about_ca_system_score_gemma":0.0004550098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006466322,"about_ca_topic_score_gemma":0.0003793462,"domain_scores_codex":[0.9972082,0.0001518114,0.0009045836,0.0007552671,0.0003270838,0.0006530833],"domain_scores_gemma":[0.9979573,0.0004286183,0.0004241843,0.0008361032,0.0002234758,0.0001302739],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03940162,0.02653252,0.2526815,0.0004500114,0.001010156,0.001001204,0.002987511,0.000003847956,0.1949484,0.0001706906,0.07672279,0.4040897],"study_design_scores_gemma":[0.3502462,0.1605795,0.0629328,0.002030266,0.000847036,0.001399163,0.0108842,0.007078195,0.1248744,0.000519812,0.275728,0.002880472],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891118,0.0007545663,0.000186865,0.006473846,0.00005979641,0.00281676,0.00004928015,0.0004799085,0.00006722],"genre_scores_gemma":[0.9932787,0.002219172,0.001566126,0.0003488502,0.00002297271,0.0008599836,0.0001527589,0.00009160405,0.001459816],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4012092,"threshold_uncertainty_score":0.999974,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","authors":[{"name":"Niels Reinmuth","is_ca":false},{"name":"Mustafa Özgüroğlu","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Domenico Galetta","is_ca":false},{"name":"İlhan Hacıbekiroğlu","is_ca":false},{"name":"Jaromı́r Roubec","is_ca":false},{"name":"Mehmet Alı Nahıt Şendur","is_ca":false},{"name":"Emilio Bria","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Hakan Harputluoğlu","is_ca":false},{"name":"Saadettin Kılıçkap","is_ca":false},{"name":"Silvia Novello","is_ca":false},{"name":"Petr Opálka","is_ca":false},{"name":"Ferdinando Riccardi","is_ca":false},{"name":"Rossitza Krasteva Ruseva","is_ca":false},{"name":"Susanne Lang","is_ca":false},{"name":"Moana Hodari","is_ca":false},{"name":"Naomi Donner","is_ca":false},{"name":"Filippo de Marinis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03270754885638696,"gpt":0.3655740603058458,"spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001013932,0.0006002625,0.001436489,0.0004714144,0.0009065908,0.00002987142,0.0009715845,0.0005695614,0.00004131265],"category_scores_gemma":[0.004238826,0.0004137187,0.0001680614,0.001703642,0.001707611,0.0001537162,0.001048716,0.001132561,0.0001251026],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001128621,"about_ca_system_score_gemma":0.000747117,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004993032,"about_ca_topic_score_gemma":0.00160756,"domain_scores_codex":[0.9953346,0.0002128643,0.001094124,0.001332652,0.0006974309,0.001328379],"domain_scores_gemma":[0.993718,0.002532617,0.0006046728,0.001996417,0.001029406,0.00011885],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1201645,0.02135406,0.2877764,0.0007361231,0.009339417,0.006065237,0.01761688,0.0001650356,0.02358657,0.0006436622,0.1560419,0.3565101],"study_design_scores_gemma":[0.2095221,0.08438363,0.31388,0.0009587323,0.001410834,0.0001687613,0.01384235,0.0006993099,0.006390626,0.001124041,0.3661595,0.001460124],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694259,0.001539929,0.0001097047,0.01876585,0.0006614402,0.006933155,0.000986919,0.0009387322,0.0006383331],"genre_scores_gemma":[0.989993,0.001212693,0.001384394,0.0008039052,0.0002767016,0.002945234,0.0007750448,0.0001363232,0.00247275],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.35505,"threshold_uncertainty_score":0.9998314,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4311139822","doi":"10.1016/j.iotech.2022.100303","title":"191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pharmacodynamics; Immunotherapy; Peripheral blood mononuclear cell; Cancer; Antigen; Immunology; Pharmacokinetics","authors":[{"name":"Antonio Jimeno","is_ca":false},{"name":"N.R. Miselis","is_ca":false},{"name":"J.C. Park","is_ca":false},{"name":"J. Jennings","is_ca":false},{"name":"N. Dhani","is_ca":true},{"name":"U. Holtick","is_ca":false},{"name":"W.T. Iams","is_ca":false},{"name":"K. Rodabaugh","is_ca":false},{"name":"N. Nair","is_ca":false},{"name":"M. Kornacker","is_ca":false},{"name":"S.M. Loughhead","is_ca":false},{"name":"H. Bernstein","is_ca":false},{"name":"R. Zwirtes","is_ca":false},{"name":"Ruqian Ji","is_ca":false},{"name":"M. Warren","is_ca":false},{"name":"Aiman Al Sharei","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007143621557407641,"gpt":0.2751821166317269,"spread":0.2680384950743192,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002963032,0.0002363975,0.0004246086,0.0004432384,0.0001140893,0.00000530174,0.0001826519,0.000155694,0.00001562399],"category_scores_gemma":[0.00007111226,0.000188582,0.00002671178,0.0005046342,0.0005826889,0.00001454662,0.0004317962,0.0002560594,3.939684e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003180745,"about_ca_system_score_gemma":0.0003003437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002097034,"about_ca_topic_score_gemma":0.002521774,"domain_scores_codex":[0.9981999,0.0001913148,0.0005075209,0.0005578337,0.000169537,0.0003738362],"domain_scores_gemma":[0.999178,0.00005312336,0.0002984247,0.0003354205,0.00008542671,0.00004961968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2630638,0.00504588,0.2482508,0.0001536896,0.0007315502,0.0004776891,0.0009478804,0.0002834555,0.09538902,0.00007039359,0.0004379063,0.3851479],"study_design_scores_gemma":[0.1749534,0.1714712,0.4575165,0.0003688645,0.0001294496,0.0008377004,0.003581956,0.0003840369,0.1654673,0.0009047493,0.02290594,0.001478871],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953519,0.002689352,0.00002258615,0.0004816973,0.00004551518,0.001120433,0.0001198247,0.00001612262,0.0001526014],"genre_scores_gemma":[0.997711,0.0007707746,0.0005650522,0.00003522769,0.000002985021,0.0004690239,0.0003433122,0.00002894616,0.00007366615],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.383669,"threshold_uncertainty_score":0.7690153,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","authors":[{"name":"R. Cohen","is_ca":false},{"name":"M.E. Elez Fernandez","is_ca":false},{"name":"N. Tarazona Llavero","is_ca":false},{"name":"N.A. Dasari","is_ca":false},{"name":"T. Mazard","is_ca":false},{"name":"C. Borg","is_ca":false},{"name":"Hélène Toussaint","is_ca":false},{"name":"Lucie Aubergeon","is_ca":false},{"name":"L. Chêne","is_ca":false},{"name":"Svetlana Balandraud","is_ca":false},{"name":"J. Fagerberg","is_ca":false},{"name":"H.J.E-V. Schmoll","is_ca":false},{"name":"Andrés Cervantes","is_ca":false},{"name":"S. Kopetz","is_ca":false},{"name":"J. Tabernero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008630389719972233,"gpt":0.2672043473917885,"spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002227765,0.0005168622,0.001198845,0.001073171,0.0001901873,0.00004092457,0.0002768926,0.0004622713,0.000250192],"category_scores_gemma":[0.00009004131,0.0004037842,0.0001454798,0.001475761,0.0007857411,0.0001630134,0.0002723648,0.0008352286,0.0001468588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002128832,"about_ca_system_score_gemma":0.0007492215,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005446671,"about_ca_topic_score_gemma":0.002082179,"domain_scores_codex":[0.9971133,0.00009665481,0.000665391,0.0008922256,0.0002776035,0.000954796],"domain_scores_gemma":[0.9988313,0.0001837146,0.0001407568,0.0005303727,0.0002204105,0.00009348745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01106288,0.003625891,0.5973467,0.0005209036,0.002853531,0.006110671,0.003704112,0.000008434145,0.01246587,0.001597195,0.002140472,0.3585633],"study_design_scores_gemma":[0.06008506,0.07517342,0.4408072,0.001154752,0.002952659,0.003772751,0.007674575,0.0005256388,0.05265911,0.003043381,0.3496512,0.002500237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762662,0.01510345,0.00001932993,0.002221068,0.0006417996,0.001420822,0.00008264675,0.0004746413,0.003770043],"genre_scores_gemma":[0.9958547,0.0004997787,0.001220943,0.0001687282,0.0000383392,0.000615173,0.0001049551,0.00008350657,0.001413929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3560631,"threshold_uncertainty_score":0.9998414,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374533","doi":"10.1016/j.iotech.2024.100886","title":"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Japanese Respiratory Society; Japan Agency for Medical Research and Development","keywords":"Adenosine; Adjuvant; Blockade; Oncology; Stage (stratigraphy); Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Receptor; Biology; Cancer","authors":[{"name":"A. De Caluwé","is_ca":false},{"name":"Xavier Catteau","is_ca":false},{"name":"Zoë Denis","is_ca":false},{"name":"Marcela Carausu","is_ca":false},{"name":"Isabelle Desmoulins","is_ca":false},{"name":"Emanuela Romano","is_ca":false},{"name":"Vincent Remouchamps","is_ca":false},{"name":"A. Baten","is_ca":false},{"name":"P. Poortmans","is_ca":false},{"name":"Cédric van Marcke","is_ca":false},{"name":"F. Rothé","is_ca":false},{"name":"Michail Ignatiadis","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Denis Larsimont","is_ca":false},{"name":"John Stagg","is_ca":true},{"name":"Christos Sotiriou","is_ca":false},{"name":"Roberto Salgado","is_ca":false},{"name":"Laurence Buisseret","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01471683082262123,"gpt":0.3441883121831741,"spread":0.3294714813605529,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003263163,0.0005042808,0.001456084,0.0007675019,0.0004507839,0.0001034878,0.0003498996,0.001038292,0.0001253973],"category_scores_gemma":[0.0005230275,0.0003680139,0.0002698172,0.0008818909,0.00122523,0.000186935,0.0001598499,0.001115911,0.000003811676],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00087084,"about_ca_system_score_gemma":0.000681272,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006745131,"about_ca_topic_score_gemma":0.001085013,"domain_scores_codex":[0.9963822,0.0005982318,0.001197853,0.0007980119,0.0002971221,0.0007266283],"domain_scores_gemma":[0.9972821,0.001357739,0.0005030677,0.0006182518,0.0001723189,0.00006651175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4450934,0.0005624332,0.0008853719,0.0001088661,0.001084851,0.00008119147,0.002453549,0.000003113951,0.01965167,0.0008057876,0.0001691263,0.5291007],"study_design_scores_gemma":[0.931918,0.02035689,0.008997117,0.0005406157,0.001853228,0.0008452957,0.002267833,0.01157222,0.003411634,0.002615052,0.01485456,0.0007674994],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9480659,0.02926477,0.0002406357,0.01538151,0.001397459,0.004910839,0.0003970997,0.0002626189,0.0000791101],"genre_scores_gemma":[0.9867837,0.008799524,0.0006527899,0.0003621245,0.0003384172,0.002387384,0.0001129855,0.00008291085,0.0004801448],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5283331,"threshold_uncertainty_score":0.9998772,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374985","doi":"10.1016/j.iotech.2024.100845","title":"102P A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lenvatinib; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Second line; Line (geometry); First line; Sorafenib","authors":[{"name":"S. Li","is_ca":false},{"name":"Qi Wen","is_ca":false},{"name":"Wen‐Tsung Huang","is_ca":false},{"name":"Long Feng","is_ca":false},{"name":"Yi Fan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03585710363949379,"gpt":0.2980887263409522,"spread":0.2622316227014584,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002582678,0.0004715911,0.001393821,0.0009148853,0.0001097056,0.000007064619,0.0002928478,0.000461532,0.0002484003],"category_scores_gemma":[0.00006146189,0.0002762038,0.0002787985,0.001664731,0.0006562851,0.00004939382,0.0001775126,0.0003772965,0.000009441033],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000397797,"about_ca_system_score_gemma":0.0004175922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003502093,"about_ca_topic_score_gemma":0.001495164,"domain_scores_codex":[0.9973235,0.0002044509,0.001022889,0.000626881,0.0003689727,0.0004533085],"domain_scores_gemma":[0.9975659,0.0004430743,0.0004332676,0.001239916,0.0002472981,0.00007059953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01067984,0.01163205,0.939401,0.0004321012,0.001140443,0.0008872969,0.001636781,0.000002813598,0.02126822,0.0002244482,0.00005613465,0.01263881],"study_design_scores_gemma":[0.02437248,0.1512819,0.1327964,0.001246019,0.001807334,0.0001302986,0.0007551555,0.0006362681,0.6807835,0.0001135671,0.005721225,0.0003558077],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897428,0.003387211,0.000004179972,0.001404409,0.0002787209,0.004336957,0.00004359153,0.0001677694,0.000634382],"genre_scores_gemma":[0.9975584,0.0001448343,0.0002615807,0.0000170126,0.00006278142,0.001042,0.00004566802,0.00007372069,0.0007939736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8066046,"threshold_uncertainty_score":0.999969,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480748","doi":"10.1016/j.iotech.2023.100601","title":"129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Refractory (planetary science); Neuroblastoma; Internal medicine; Population; Bone marrow; Phases of clinical research; Interim analysis; Oncology; Nuclear medicine; Gastroenterology; Clinical trial","authors":[{"name":"Brian H. Kushner","is_ca":false},{"name":"Jaume Mora","is_ca":false},{"name":"Gcf Chan","is_ca":false},{"name":"Daniel A. Morgenstern","is_ca":true},{"name":"Loredana Amoroso","is_ca":false},{"name":"K. Nysom","is_ca":false},{"name":"Joerg Faber","is_ca":false},{"name":"Arthur Wingerter","is_ca":false},{"name":"Melissa Bear","is_ca":false},{"name":"M. During","is_ca":false},{"name":"Karen Tornøe","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007183636098152099,"gpt":0.2752357812312524,"spread":0.2680521451331003,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000267841,0.0004473234,0.0009640403,0.001493198,0.0002045992,0.00002537717,0.0002790366,0.0005404781,0.00009091944],"category_scores_gemma":[0.0009761414,0.0003634429,0.00007132353,0.001897123,0.0008647321,0.0001710421,0.000353414,0.001139818,0.0002860738],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002661515,"about_ca_system_score_gemma":0.0003488007,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001989439,"about_ca_topic_score_gemma":0.0001079539,"domain_scores_codex":[0.9968709,0.0002900473,0.0005302696,0.0008751633,0.0004304994,0.001003158],"domain_scores_gemma":[0.9979212,0.0005912124,0.0002807516,0.0008108162,0.0001841785,0.0002118478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01966501,0.01693058,0.6692023,0.0001915344,0.002052031,0.0137199,0.000264098,0.00001126456,0.08288424,0.0007455801,0.01249421,0.1818393],"study_design_scores_gemma":[0.06351068,0.04639689,0.8438491,0.0002055289,0.0004468852,0.0004753356,0.0002385461,0.0000239842,0.02428387,0.000684099,0.01927466,0.0006104706],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946305,0.0004657304,0.000004590066,0.002426938,0.0001630041,0.001338901,0.00010771,0.0006809448,0.0001817222],"genre_scores_gemma":[0.9980025,0.0005363307,0.0002848319,0.0001922456,0.0000165004,0.0002530491,0.0002955566,0.00009380177,0.000325147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1812288,"threshold_uncertainty_score":0.9998817,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117306841","doi":"10.1016/j.iotech.2025.101399","title":"402P TMEM33 loss enhances CD8+ T cell functionality and tumour control","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Discovery Centre","funders":"","keywords":"T cell; Cytotoxic T cell; Immune system; T lymphocyte; Cell","authors":[{"name":"M.T. Jackson","is_ca":false},{"name":"T. Zhao","is_ca":false},{"name":"G.B. Milotay","is_ca":false},{"name":"I. Pedroza-Pacheco","is_ca":false},{"name":"A. Grover","is_ca":false},{"name":"D. Gabrilovich","is_ca":false},{"name":"J. Rehwinkel","is_ca":true},{"name":"B.P. Fairfax","is_ca":false},{"name":"E. Honoré","is_ca":false},{"name":"D. Withers","is_ca":false},{"name":"E.E. Parkes","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006170921108255087,"gpt":0.2813748800299773,"spread":0.2752039589217223,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004001701,0.0002425975,0.0006345022,0.0004661756,0.0001975718,0.00001312116,0.0002145889,0.0007092048,0.0003119681],"category_scores_gemma":[0.0001044063,0.0002148319,0.0001234722,0.0005883505,0.001292406,0.00006088508,0.0001049767,0.0004811604,0.00003517649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002973483,"about_ca_system_score_gemma":0.0004579911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000088184,"about_ca_topic_score_gemma":0.00006601346,"domain_scores_codex":[0.9984351,0.00008575983,0.0004732031,0.0004685696,0.0001143823,0.0004229243],"domain_scores_gemma":[0.9989662,0.0002187884,0.0001668473,0.0004506107,0.0001528802,0.00004473661],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004382222,0.0004611397,0.03087655,0.0001101334,0.0006021964,0.0001072571,0.00006666002,4.746217e-7,0.8847306,0.002983088,0.004755718,0.07092391],"study_design_scores_gemma":[0.02070233,0.002779986,0.06511848,0.0001473731,0.0004871635,0.0007891965,0.0009891632,0.00003542272,0.2785891,0.007435215,0.6224901,0.0004364222],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9301664,0.02135543,0.001100207,0.03189094,0.001250091,0.0006786098,0.00001940486,0.0003950353,0.01314387],"genre_scores_gemma":[0.991855,0.00145842,0.0004055513,0.003195489,0.00006923207,0.000164651,0.00001306609,0.0000160125,0.002822613],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6177344,"threshold_uncertainty_score":0.8760593,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117310539","doi":"10.1016/j.iotech.2025.101097","title":"12P Stromal CD73 expression in early-stage high-risk luminal B-like breast cancer: An exploratory analysis from the randomized Neo-CheckRay trial","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Stromal cell; Exploratory analysis; Adenosine; Breast cancer; Immune system; Pathological; Randomized controlled trial; Clinical trial","authors":[{"name":"Z. Denis","is_ca":false},{"name":"A. De Caluwe","is_ca":false},{"name":"E. Romano","is_ca":false},{"name":"J. Stagg","is_ca":true},{"name":"T. Yin","is_ca":false},{"name":"J. Dhont","is_ca":false},{"name":"F. Lifrange","is_ca":false},{"name":"M. Carausu","is_ca":false},{"name":"C. Sotiriou","is_ca":false},{"name":"L. Buisseret","is_ca":false},{"name":"X. Catteau","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006197744301364331,"gpt":0.2698546813712414,"spread":0.263656937069877,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009908464,0.0003760059,0.001058531,0.0004987527,0.0002588064,0.00003395095,0.0009754262,0.001150622,0.0001457438],"category_scores_gemma":[0.0002640097,0.0002879183,0.0003347083,0.001008424,0.0007354299,0.00001911065,0.0005022051,0.0006869924,0.000005594538],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001078976,"about_ca_system_score_gemma":0.0004288243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003011117,"about_ca_topic_score_gemma":0.001488163,"domain_scores_codex":[0.9966128,0.001053682,0.0008176115,0.0008257659,0.0001572807,0.000532868],"domain_scores_gemma":[0.9979678,0.0002625491,0.0004485237,0.001099109,0.0001643275,0.00005767607],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4206907,0.0009660354,0.0847111,0.0000139083,0.004847915,0.0001399372,0.0008340204,0.001489911,0.4663815,0.0005713742,0.006308545,0.01304509],"study_design_scores_gemma":[0.7292353,0.002448664,0.02193553,0.0001402377,0.004019558,0.00003100164,0.0053413,0.0006454202,0.1897703,0.002198582,0.04278914,0.001445017],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860595,0.008407504,0.002004174,0.001588344,0.000895908,0.000701313,0.0001695737,0.00008516558,0.00008847954],"genre_scores_gemma":[0.9954635,0.001654961,0.0007644832,0.0003942342,0.0004365331,0.0006973657,0.0002389274,0.0000292389,0.0003207625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3085446,"threshold_uncertainty_score":0.9999573,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117316366","doi":"10.1016/j.iotech.2025.101405","title":"408P Calpain as a novel therapeutic target in breast cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Breast cancer; Calpain; Cancer; Human breast; Disease","authors":[{"name":"D. Harper","is_ca":true},{"name":"I. Shapovalov","is_ca":true},{"name":"J.Y. Min","is_ca":true},{"name":"B.J. Laight","is_ca":true},{"name":"S. Cockburn","is_ca":true},{"name":"A. Aaron","is_ca":true},{"name":"Y. Gao","is_ca":true},{"name":"P.A. Greer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004559655176082028,"gpt":0.2819368003166113,"spread":0.2773771451405293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002795139,0.0001962472,0.000266129,0.0004385668,0.0001000311,0.000009591406,0.000289126,0.0009521501,0.0001713166],"category_scores_gemma":[0.00007063807,0.0001889134,0.00008282052,0.0006017752,0.0003459411,0.000004526837,0.0001879707,0.0002898111,0.0000199771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001835422,"about_ca_system_score_gemma":0.0004844859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001518297,"about_ca_topic_score_gemma":0.000223255,"domain_scores_codex":[0.9987046,0.00008935835,0.0003241815,0.0004505518,0.00006803157,0.0003632421],"domain_scores_gemma":[0.9993068,0.00002356583,0.00009920566,0.0004354552,0.0001049517,0.00003000318],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004227845,0.0002962803,0.0167539,0.00001494018,0.0001392629,0.000007839653,0.00002402439,0.0001126563,0.9296818,0.006276868,0.001860941,0.04440865],"study_design_scores_gemma":[0.00498143,0.0005533932,0.03116335,0.00007740186,0.00005755819,0.0003438161,0.0005346194,0.0006515048,0.17064,0.009165324,0.7813051,0.0005264974],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9122859,0.01006792,0.01657928,0.05062465,0.001859914,0.001127203,0.00005036803,0.0002570157,0.007147746],"genre_scores_gemma":[0.992755,0.0003897818,0.0005292237,0.002724645,0.00007673888,0.0003873432,0.00005190906,0.00002126726,0.003064068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7794442,"threshold_uncertainty_score":0.7703666,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117307022","doi":"10.1016/j.iotech.2025.101348","title":"351P Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Renal cell carcinoma; Immune system; Kidney cancer; Receptor; Cell; Immunotherapy; T cell; Kidney","authors":[{"name":"K. Shah","is_ca":false},{"name":"N.J. Salgia","is_ca":false},{"name":"S.V. Ambarkhane","is_ca":false},{"name":"B. Cipriani","is_ca":false},{"name":"D. Memon","is_ca":true},{"name":"M.J. Oliva Martin","is_ca":false},{"name":"M. Zugman","is_ca":false},{"name":"S. Jaime-Casas","is_ca":false},{"name":"P. Zang","is_ca":false},{"name":"V. Abreu de Goes","is_ca":false},{"name":"J. Hsu","is_ca":false},{"name":"S.K. Pal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009426331137015345,"gpt":0.2507016620731092,"spread":0.2412753309360939,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007831286,0.0005029716,0.001525333,0.00144527,0.0001011692,0.00001068227,0.0004501185,0.000820621,0.0001546426],"category_scores_gemma":[0.0001645601,0.0004224328,0.0002033884,0.001825596,0.0003916545,0.0000886685,0.0001847953,0.0009589361,0.00004702933],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002278988,"about_ca_system_score_gemma":0.001329602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004113482,"about_ca_topic_score_gemma":0.0001817484,"domain_scores_codex":[0.9966825,0.0002398325,0.001161995,0.0007038032,0.0003740818,0.0008378162],"domain_scores_gemma":[0.9974046,0.0003164079,0.0008495316,0.0009644887,0.0003980524,0.00006690279],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001949928,0.002537424,0.06888941,0.0002713438,0.0003675852,0.000177188,0.00031377,0.00001959176,0.9234757,0.000376587,0.00008697389,0.001534429],"study_design_scores_gemma":[0.01854048,0.005114599,0.04347412,0.0002027946,0.0006346227,0.00009164888,0.001080181,0.0002473712,0.9268457,0.0005385861,0.002868941,0.0003610068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822763,0.006884012,0.0007141135,0.004093566,0.0001992711,0.002654958,0.00001991168,0.0001703975,0.002987452],"genre_scores_gemma":[0.983256,0.00007307398,0.01200377,0.0001552708,0.00001745294,0.0008683223,0.00008271816,0.00006167147,0.003481657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02541529,"threshold_uncertainty_score":0.9998227,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117320530","doi":"10.1016/j.iotech.2025.101565","title":"350P Demystifying the biology behind a high neutrophil-to-lymphocyte ratio in gastroesophageal adenocarcinoma patients","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Disease; Cancer; MEDLINE; Esophageal adenocarcinoma","authors":[{"name":"I. Dhoparee Doomah","is_ca":true},{"name":"A. Brassard","is_ca":true},{"name":"Q. Qiu","is_ca":true},{"name":"R. Rohanizadeh","is_ca":true},{"name":"S. Leo","is_ca":true},{"name":"F. Bourdeau","is_ca":true},{"name":"B. Giannias","is_ca":true},{"name":"L. Ferri","is_ca":true},{"name":"J. Cools-Lartigue","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00567843413252664,"gpt":0.2934156528470926,"spread":0.287737218714566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005083781,0.0004177,0.0008440035,0.001690469,0.0003040837,0.00002052625,0.0008721797,0.001028854,0.00009229778],"category_scores_gemma":[0.0007102067,0.0003433503,0.0001511162,0.001317898,0.001004439,0.00007473204,0.000787597,0.0008012751,0.0001171788],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00127421,"about_ca_system_score_gemma":0.0008214711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008166132,"about_ca_topic_score_gemma":0.00007921387,"domain_scores_codex":[0.996798,0.0003336887,0.0009293063,0.0007967906,0.0001616217,0.0009806072],"domain_scores_gemma":[0.9980017,0.0003037383,0.0002415899,0.001094038,0.0002520557,0.0001069017],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001803537,0.0005103255,0.9250184,0.00006139807,0.0003597225,0.0003342505,0.0002201379,0.000008739028,0.01466249,0.006057573,0.001246383,0.04971708],"study_design_scores_gemma":[0.01018487,0.001776215,0.9561902,0.0001836618,0.0003463429,0.0001511754,0.0004106853,0.0001402639,0.01373255,0.003692532,0.01284813,0.0003434182],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767578,0.003189142,0.0002798611,0.01534552,0.001078224,0.001926458,0.00002274821,0.0003354954,0.00106476],"genre_scores_gemma":[0.9934948,0.00007942594,0.002050945,0.00302404,0.00008184101,0.001016608,0.00005777281,0.0000426445,0.0001519093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04937366,"threshold_uncertainty_score":0.9999018,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117306831","doi":"10.1016/j.iotech.2025.101226","title":"142P Infusion time of adjuvant PD-1 therapy in high-risk resectable melanoma: Accounting for distance from clinic, scheduling changes over time, and appropriately adjusting p-values in SWOG S1404","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Merck; Bristol-Myers Squibb","keywords":"Scheduling (production processes); Adjuvant; Adjuvant therapy; Continuous infusion","authors":[{"name":"S.P. Patel","is_ca":false},{"name":"K. Kendra","is_ca":false},{"name":"K.F. Grossmann","is_ca":false},{"name":"E. Buchbinder","is_ca":false},{"name":"N.I. Khushalani","is_ca":false},{"name":"Z. Eroglu","is_ca":false},{"name":"S. Chandra","is_ca":false},{"name":"G. Doolittle","is_ca":false},{"name":"J.M. Kirkwood","is_ca":false},{"name":"A. Ikeguchi","is_ca":false},{"name":"C. Mihalcioiu","is_ca":true},{"name":"C.L. Cowey","is_ca":false},{"name":"S.A. Reddy","is_ca":false},{"name":"D. Johnson","is_ca":false},{"name":"M. Taylor","is_ca":false},{"name":"V. Sondak","is_ca":false},{"name":"A. Ribas","is_ca":false},{"name":"M. Othus","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01078010469760657,"gpt":0.2866931739268872,"spread":0.2759130692292807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009491389,0.0002552707,0.0009863393,0.001087978,0.0001194185,0.00001404535,0.0002382483,0.0006924423,0.0001303945],"category_scores_gemma":[0.001066378,0.0002422109,0.00006397293,0.0007783434,0.0002663647,0.00006956906,0.0003153842,0.0005805481,0.00001306617],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002791113,"about_ca_system_score_gemma":0.000135376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009981842,"about_ca_topic_score_gemma":0.001103287,"domain_scores_codex":[0.9979408,0.000123214,0.0007664305,0.0005829456,0.0001256135,0.0004610362],"domain_scores_gemma":[0.9981881,0.0007428156,0.0004511142,0.0004723769,0.0001182692,0.00002736777],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.005957569,0.0007536191,0.1363605,0.000243757,0.0004050974,0.0001365023,0.0008831305,0.0000625733,0.3684234,0.0004914611,0.0003297448,0.4859527],"study_design_scores_gemma":[0.09550269,0.02254778,0.4348951,0.007083962,0.001370409,0.0002985501,0.01223277,0.06753902,0.235592,0.03456362,0.08559752,0.00277652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898685,0.005534556,0.0003455519,0.001571604,0.0003628659,0.001339847,0.00002717691,0.0001793981,0.0007705485],"genre_scores_gemma":[0.9898275,0.002669365,0.00599435,0.0002357364,0.0000659459,0.0002235444,0.00003643671,0.00003431299,0.0009127889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4831761,"threshold_uncertainty_score":0.9877075,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","authors":[{"name":"C. Ragulan","is_ca":true},{"name":"M. Herpels","is_ca":true},{"name":"G. Box","is_ca":false},{"name":"Y. Ikami","is_ca":true},{"name":"R. Luo","is_ca":true},{"name":"L. Howell","is_ca":true},{"name":"E. Westlund","is_ca":true},{"name":"A. De Haven Brandon","is_ca":false},{"name":"N. Guppy","is_ca":false},{"name":"E. Wennerberg","is_ca":false},{"name":"J. Ishihara","is_ca":false},{"name":"A. Sadanandam","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01692823134436916,"gpt":0.3463640821661589,"spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007699439,0.0003801344,0.001300327,0.001790158,0.00017713,0.00002077651,0.0004187975,0.0008966589,0.002161692],"category_scores_gemma":[0.0003985746,0.0003363187,0.0001483326,0.001252775,0.001136366,0.0000946428,0.0003762686,0.001085126,0.00002576269],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000793934,"about_ca_system_score_gemma":0.0005996829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009315402,"about_ca_topic_score_gemma":0.0002966169,"domain_scores_codex":[0.9971619,0.000320802,0.0007577194,0.000707639,0.0002257574,0.0008261502],"domain_scores_gemma":[0.9979715,0.0004937472,0.0001761731,0.001144902,0.0001463579,0.00006726763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001834498,0.0003220844,0.02397527,0.0001168879,0.0005082222,0.00018214,0.000274012,0.000002014099,0.6719601,0.0005756886,0.0004498241,0.2997993],"study_design_scores_gemma":[0.01794814,0.002636494,0.06318586,0.001608323,0.0005372454,0.0009678451,0.002843756,0.0001898182,0.4751865,0.00460934,0.4295686,0.0007181347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9337994,0.04133784,0.00006646678,0.01749442,0.0005607539,0.001372961,0.0000207664,0.000282924,0.005064459],"genre_scores_gemma":[0.9609759,0.0272451,0.001166551,0.0006136368,0.00003424645,0.000835129,0.00001555124,0.00006637912,0.009047446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4291187,"threshold_uncertainty_score":0.9999089,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117291323","doi":"10.1016/j.iotech.2025.101225","title":"141P Clinical study of camrelizumab combined with SOX in adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma: Interim report","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Colorado Denver; University of Pittsburgh; Medical Center, University of Pittsburgh; Vanderbilt University Medical Center; McGill University Health Centre; McGill University; Northwestern University; University of Texas MD Anderson Cancer Center; School of Medicine, Stanford University; Vanderbilt University; Moffitt Cancer Center; Ohio State University","keywords":"Clinical study; Gastroesophageal Junction; Adjuvant therapy; Clinical trial; Adjuvant; Interim; Interim analysis","authors":[{"name":"Q. Yi","is_ca":false},{"name":"H. Liu","is_ca":false},{"name":"J. Liu","is_ca":false},{"name":"Z. Xiao","is_ca":false},{"name":"Q. Li","is_ca":false},{"name":"C. Wei","is_ca":false},{"name":"M. Jiao","is_ca":false},{"name":"C. Su","is_ca":false},{"name":"C. Wang","is_ca":false},{"name":"K. Li","is_ca":false},{"name":"L. Ma","is_ca":false},{"name":"M. Li","is_ca":false},{"name":"Y. Kong","is_ca":false},{"name":"Y. Wen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03616686054081508,"gpt":0.384055794376691,"spread":0.3478889338358759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006963458,0.0002795165,0.001333554,0.001354909,0.00006972982,0.000006735231,0.000324108,0.000405592,0.00005017293],"category_scores_gemma":[0.0003378506,0.0002039028,0.0001220666,0.001475803,0.0003896788,0.00005458442,0.0001987347,0.0005506924,0.000002216232],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004131847,"about_ca_system_score_gemma":0.0007038353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001555693,"about_ca_topic_score_gemma":0.0006805374,"domain_scores_codex":[0.997346,0.0001111461,0.001308718,0.0006096067,0.0001616311,0.0004628639],"domain_scores_gemma":[0.9981774,0.0002503239,0.000505743,0.0007846348,0.0002422712,0.00003964423],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02729008,0.003645312,0.8907109,0.00006534924,0.0006629932,0.001347234,0.0001578573,0.000003959629,0.0002879116,0.0001624825,0.002069945,0.07359596],"study_design_scores_gemma":[0.06145296,0.08204379,0.8425156,0.0001156646,0.0005246263,0.0008029537,0.006576852,0.00005803731,0.0004607145,0.0001920013,0.005077189,0.000179546],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903341,0.0007897355,0.001474277,0.002687552,0.0009559845,0.003208825,0.000002427254,0.0001853532,0.0003617669],"genre_scores_gemma":[0.9958884,0.0001869793,0.00150393,0.0002822653,0.000049396,0.0006978055,0.00002587446,0.00002787221,0.001337533],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07839848,"threshold_uncertainty_score":0.8314915,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374307","doi":"10.1016/j.iotech.2024.100796","title":"168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"Institut National Du Cancer; Eisai; Fondation ARC pour la Recherche sur le Cancer; Seagen; Astellas Pharma; NuCana; Sanofi; Exelixis; BeiGene; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Conjugate; Antibody-drug conjugate; Antibody; Medicine; Drug; Cancer research; Monoclonal antibody; Pharmacology; Immunology; Mathematics","authors":[{"name":"G. Curigliano","is_ca":false},{"name":"P. Cassier","is_ca":false},{"name":"Gennaro Daniele","is_ca":false},{"name":"John Hilton","is_ca":true},{"name":"A. Italiano","is_ca":false},{"name":"Shigeki KOGANEMARU","is_ca":false},{"name":"Rubén Dario Kowalyszyn","is_ca":false},{"name":"P. LoRusso","is_ca":false},{"name":"V. Moreno Garcia","is_ca":false},{"name":"M.E. Olmedo García","is_ca":false},{"name":"Herman Andrés Perroud","is_ca":false},{"name":"Wasif M. Saif","is_ca":false},{"name":"Stefan N. Symeonides","is_ca":false},{"name":"A. Aziez","is_ca":false},{"name":"Rana Anjum","is_ca":false},{"name":"John LaMacchia","is_ca":false},{"name":"Harjeet Sembhi","is_ca":false},{"name":"Nirav Ratia","is_ca":false},{"name":"N. Yamamoto","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007515845738382482,"gpt":0.342843778635392,"spread":0.3353279328970095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005149296,0.0004168155,0.001095304,0.001123495,0.0001243392,0.00001553169,0.000449987,0.0005295505,0.0001122152],"category_scores_gemma":[0.0003309491,0.0003381351,0.00009431264,0.001775859,0.0008693777,0.0001607806,0.000267512,0.001109316,0.00002586173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003092317,"about_ca_system_score_gemma":0.0003833745,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001451803,"about_ca_topic_score_gemma":0.00006412491,"domain_scores_codex":[0.996824,0.0001737563,0.001104057,0.0008666466,0.0003810858,0.000650473],"domain_scores_gemma":[0.9980264,0.0001439881,0.000362492,0.0009945215,0.0003392069,0.0001334215],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004772998,0.02611073,0.1237507,0.0004617145,0.0006013653,0.001206282,0.002479078,0.00002445996,0.7265956,0.00224207,0.002275189,0.1094798],"study_design_scores_gemma":[0.1813253,0.1309329,0.1968981,0.00891383,0.0026623,0.001108995,0.01155141,0.01288767,0.3773166,0.01471587,0.05724023,0.004446801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866242,0.0005820451,0.0009780247,0.005537336,0.0001763977,0.004834861,0.0000310532,0.001057795,0.0001782863],"genre_scores_gemma":[0.9902908,0.00007149248,0.007647209,0.0001694351,0.00003089284,0.001360498,0.0002112552,0.00007657285,0.0001418641],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.349279,"threshold_uncertainty_score":0.9999071,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","authors":[{"name":"S.N. Symeonides","is_ca":false},{"name":"T.R.J. Evans","is_ca":false},{"name":"D. A. Fennell","is_ca":false},{"name":"V. Coyle","is_ca":false},{"name":"I. Karydis","is_ca":false},{"name":"A. Oswald","is_ca":false},{"name":"L. Sweeting","is_ca":false},{"name":"C. Macbride","is_ca":false},{"name":"J. McQueen","is_ca":false},{"name":"A. Coleman","is_ca":false},{"name":"T. Wynn","is_ca":false},{"name":"K. Boukas","is_ca":false},{"name":"A. Serrels","is_ca":false},{"name":"C.H.H. Ottensmeier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02047705227220095,"gpt":0.385868474467102,"spread":0.3653914221949011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005678727,0.0002250549,0.0008458476,0.001215705,0.00009667034,0.000004264208,0.0003087383,0.0005265932,0.00003334193],"category_scores_gemma":[0.001533569,0.0001828225,0.00008111332,0.001548573,0.000947697,0.00005108942,0.0006470519,0.0009341067,0.000004025514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002540742,"about_ca_system_score_gemma":0.0005161129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001517608,"about_ca_topic_score_gemma":0.0003313543,"domain_scores_codex":[0.9974751,0.0002973048,0.001002712,0.0005088039,0.0002714091,0.0004446878],"domain_scores_gemma":[0.9980329,0.0003681613,0.0003880251,0.0008860187,0.0002827096,0.00004213233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01015936,0.004452121,0.01246272,0.0001243534,0.0001274474,0.000270594,0.000714033,0.00002928047,0.9100993,0.0003791927,0.0004020024,0.06077955],"study_design_scores_gemma":[0.07735017,0.01485071,0.079034,0.0004736629,0.0001922603,0.0003840043,0.008041905,0.0002365061,0.8131578,0.001467156,0.004561056,0.000250787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902028,0.0006929335,0.0000346344,0.004205914,0.0001685643,0.00158331,0.00001788273,0.00006724778,0.003026683],"genre_scores_gemma":[0.9986566,0.0002233197,0.0002527495,0.0001017371,0.000008718085,0.0001347147,0.00001168222,0.00001941969,0.0005910001],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09694156,"threshold_uncertainty_score":0.7455285,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407087806","doi":"10.1016/j.iotech.2025.101042","title":"Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Meta-analysis; Overall survival; Correlation; Melanoma; Oncology; Internal medicine; Survival analysis; Medicine; Biology; Mathematics; Cancer research","authors":[{"name":"LP Leung","is_ca":false},{"name":"John M. Kirkwood","is_ca":false},{"name":"S. Srinivasan","is_ca":false},{"name":"M Dyer","is_ca":false},{"name":"A Qian","is_ca":false},{"name":"MM. Pourrahmat","is_ca":false},{"name":"Ellen Kasireddy","is_ca":false},{"name":"J. Robert May","is_ca":false},{"name":"Andriy Moshyk","is_ca":false},{"name":"Murat Kurt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07049526614308026,"gpt":0.3109782898953646,"spread":0.2404830237522843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007039182,0.0002659966,0.001547967,0.001962932,0.0001001117,0.000008641941,0.0003010114,0.00046082,0.0001934381],"category_scores_gemma":[0.0002775869,0.0002550133,0.0002384757,0.000635388,0.0001859816,0.00006703721,0.0007726529,0.0003726245,0.00000167708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002356026,"about_ca_system_score_gemma":0.00010911,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042537,"about_ca_topic_score_gemma":0.005191551,"domain_scores_codex":[0.9979236,0.0001141959,0.0008160754,0.0005778429,0.0002298348,0.0003384165],"domain_scores_gemma":[0.9983625,0.0002718916,0.0003256805,0.000816396,0.0001628184,0.0000607119],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.004908407,0.002670954,0.05468383,0.0003777705,0.1945864,0.0007140423,0.006535223,0.0004539618,0.02174198,0.1243359,0.0004562545,0.5885352],"study_design_scores_gemma":[0.04782828,0.02383979,0.2905119,0.0004336413,0.2873493,0.000181257,0.07824183,0.008894076,0.01428687,0.05313862,0.1923185,0.002976027],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9546247,0.01119838,0.001037179,0.01279692,0.0008398838,0.001086951,0.00009257749,0.000209038,0.01811442],"genre_scores_gemma":[0.9927712,0.001948251,0.0006834015,0.000231466,0.00001927297,0.0002038314,0.0000513401,0.00001502849,0.004076192],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5855592,"threshold_uncertainty_score":0.9999902,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117304384","doi":"10.1016/j.iotech.2025.101199","title":"114P Exploring the role of FES kinase in natural killer cells to enhance immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Immunotherapy; Kinase; Immune system; Natural killer cell; Cancer immunotherapy; Tyrosine kinase","authors":[{"name":"A.A. Varty-Higgs","is_ca":true},{"name":"J. Simonetti","is_ca":true},{"name":"B.J. Laight","is_ca":true},{"name":"P.A. Greer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006114528020794343,"gpt":0.2639369299625833,"spread":0.257822401941789,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004249981,0.0002953617,0.0005896048,0.001112243,0.0002359806,0.00001101666,0.0008428944,0.000586688,0.0004141676],"category_scores_gemma":[0.0001900197,0.0002395524,0.0001465972,0.001164838,0.0005596268,0.0001510504,0.0003255975,0.001094486,0.0004160292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002953132,"about_ca_system_score_gemma":0.0001501295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003052343,"about_ca_topic_score_gemma":0.0001408228,"domain_scores_codex":[0.9978564,0.000301769,0.0007590487,0.0004565299,0.00004112757,0.0005851438],"domain_scores_gemma":[0.9983965,0.0003794219,0.0002277288,0.0008204447,0.0001659605,0.000009937449],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006551312,0.0002140488,0.0006351573,0.000006578517,0.0001678012,0.000003303743,0.0006163558,0.00001045434,0.8058932,0.00290164,0.002621734,0.1862746],"study_design_scores_gemma":[0.0005933262,0.0002732177,0.001344308,0.0000434318,0.00001284374,0.00002032055,0.002636516,0.000003094013,0.5709966,0.0005185508,0.4234327,0.000125096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9459072,0.02246913,0.0001646309,0.004523468,0.0204581,0.0007290313,0.00000192348,0.000238331,0.005508144],"genre_scores_gemma":[0.9855466,0.0008883482,0.000154938,0.0008131405,0.00001704282,0.0004373171,0.00001595056,0.00002337305,0.0121033],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.420811,"threshold_uncertainty_score":0.9768664,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310923624","doi":"10.1016/j.iotech.2022.100230","title":"241P Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Center (category theory); Retrospective cohort study; Health care; Immunotherapy; Toxicity; Internal medicine; Family medicine; Oncology; Cancer; Political science","authors":[{"name":"M. Swaminathan","is_ca":false},{"name":"A. Angelakas","is_ca":false},{"name":"Monica L. Baxter","is_ca":false},{"name":"J. Cotton","is_ca":false},{"name":"C.B. Dobeson","is_ca":false},{"name":"L. Feeney","is_ca":false},{"name":"A.C. Gault","is_ca":false},{"name":"D.J. Hughes","is_ca":false},{"name":"Cheryl Page Jones","is_ca":false},{"name":"R. Lee","is_ca":false},{"name":"Shahrauz Mughal","is_ca":false},{"name":"S.P. Parikh","is_ca":false},{"name":"M. Pritchard","is_ca":false},{"name":"L.J. Rodgers","is_ca":false},{"name":"M.P. Rowe","is_ca":false},{"name":"A.T. Salawu","is_ca":true},{"name":"R. Shotton","is_ca":false},{"name":"Nadina Tinsley","is_ca":false},{"name":"Ann Tivey","is_ca":false},{"name":"A.C. Olsson-Brown","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05952476980682447,"gpt":0.4100764466070851,"spread":0.3505516768002606,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002304701,0.0002552818,0.0007110309,0.0006750862,0.000734471,0.00001246939,0.0003866329,0.0001537109,0.00002332439],"category_scores_gemma":[0.0002929004,0.0001491169,0.0001078681,0.001663275,0.0007052731,0.00004545688,0.0001431638,0.0007383948,2.365282e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00250837,"about_ca_system_score_gemma":0.0007807809,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007352727,"about_ca_topic_score_gemma":0.001886232,"domain_scores_codex":[0.9969029,0.001113203,0.0005441201,0.0004439576,0.0004512289,0.0005445197],"domain_scores_gemma":[0.9978352,0.0009162865,0.0003020538,0.0003361015,0.0005841107,0.00002626757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01370574,0.0125854,0.9519628,0.00001181336,0.001038248,0.00003175252,0.01209001,0.000002142857,0.004977296,0.0003883158,0.0003365237,0.002869999],"study_design_scores_gemma":[0.08393738,0.08567607,0.712142,0.00004722605,0.0001112209,0.0001876572,0.08705856,0.00006083765,0.0003220891,0.0002416424,0.02997163,0.0002436825],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774579,0.0005127418,0.00005013264,0.01653739,0.0001005449,0.004785206,0.0004837496,0.00004057743,0.00003169038],"genre_scores_gemma":[0.9956472,0.00003170942,0.000522679,0.0009588327,0.00001251407,0.002616145,0.0001393386,0.00002962208,0.00004195067],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2398207,"threshold_uncertainty_score":0.6559302,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117317538","doi":"10.1016/j.iotech.2025.101406","title":"409P Spatial profiling of tumour-infiltrating B cells reveals immune shifts in rapidly progressing cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Immune system; Antibody; Profiling (computer programming); Gene expression profiling; B cell; Phenotype","authors":[{"name":"S. Yangngam","is_ca":false},{"name":"C.J. O'Rourke","is_ca":false},{"name":"O. Nousias","is_ca":false},{"name":"J. Andersen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0122694007136765,"gpt":0.3009349530357847,"spread":0.2886655523221082,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006463114,0.0003699839,0.001362736,0.00136574,0.0001625899,0.0000156934,0.0004144768,0.0006954469,0.00003020826],"category_scores_gemma":[0.0003726619,0.0003571197,0.0002196592,0.001400061,0.0007180355,0.00009725805,0.0003850545,0.0009118298,0.000009683588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004247301,"about_ca_system_score_gemma":0.0006162236,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002521915,"about_ca_topic_score_gemma":0.0001241856,"domain_scores_codex":[0.9970922,0.0001377001,0.001214536,0.0006125686,0.0001987272,0.0007442984],"domain_scores_gemma":[0.9983415,0.0002259596,0.000448156,0.0007007672,0.0002360815,0.0000475414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004205119,0.0003063538,0.2447675,0.0002668001,0.0002332939,0.0002236841,0.0004889926,0.000003862979,0.7107884,0.0008875951,0.0001535665,0.0414595],"study_design_scores_gemma":[0.006011869,0.001383716,0.3711273,0.00109543,0.0002699922,0.0001443679,0.002403043,0.000131412,0.6147313,0.001071644,0.001257471,0.0003724892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9645916,0.02168924,0.0002557478,0.004579199,0.0007165562,0.001193459,0.000007867203,0.0002574505,0.006708946],"genre_scores_gemma":[0.9925792,0.0001870989,0.006432693,0.0002668545,0.00008635649,0.0002522261,0.00001888129,0.00003686776,0.0001398162],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1263598,"threshold_uncertainty_score":0.9998881,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","authors":[{"name":"Ferdinandos Skoulidis","is_ca":false},{"name":"Kristof Cuppens","is_ca":false},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Vamsidhar Velcheti","is_ca":false},{"name":"D.H. Lee","is_ca":false},{"name":"M.T. Lin","is_ca":false},{"name":"T.M. Fernando","is_ca":false},{"name":"S. Li","is_ca":false},{"name":"David Bradley","is_ca":false},{"name":"Marija Crnković","is_ca":false},{"name":"Mariann Mathisen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01084802645926599,"gpt":0.3612404445660097,"spread":0.3503924181067438,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002007547,0.000490348,0.001265652,0.001614612,0.0002086425,0.000008931451,0.0002955354,0.0005732311,0.0001720492],"category_scores_gemma":[0.00009090943,0.0004429165,0.0001117543,0.002290552,0.0003301138,0.00008035707,0.000160985,0.0005237858,0.00000683182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008524255,"about_ca_system_score_gemma":0.000953555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009707676,"about_ca_topic_score_gemma":0.0009864597,"domain_scores_codex":[0.997312,0.0001031811,0.0008206383,0.0007935146,0.0002179757,0.0007526798],"domain_scores_gemma":[0.9982427,0.0002568474,0.0004174306,0.0007527781,0.0002204963,0.000109788],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.00718399,0.01341579,0.5997234,0.0004642439,0.002045144,0.00116373,0.009420363,0.0003661953,0.2245388,0.0000689581,0.00120869,0.1404007],"study_design_scores_gemma":[0.4913401,0.03997913,0.291059,0.001073586,0.003881731,0.0002108718,0.01571398,0.01373458,0.1357991,0.0002356057,0.005312706,0.001659473],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.989275,0.003258319,0.00005904553,0.002360654,0.0002987765,0.003485511,0.00008273472,0.0004635262,0.000716422],"genre_scores_gemma":[0.9959431,0.0008154053,0.0005769343,0.000206181,0.0000326499,0.001552734,0.0001262161,0.00009118772,0.0006555333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4841562,"threshold_uncertainty_score":0.9998022,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480990","doi":"10.1016/j.iotech.2023.100488","title":"19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Stichting Tegen Kanker","keywords":"Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Value (mathematics); Exploratory analysis; Medicine; Cancer; Statistics; Mathematics; Computer science; Data science","authors":[{"name":"Zoe Davey","is_ca":false},{"name":"Paulus Kristanto","is_ca":false},{"name":"Xavier Catteau","is_ca":false},{"name":"Delphine Vincent","is_ca":false},{"name":"Véronique Debien","is_ca":false},{"name":"Elisa Agostinetto","is_ca":false},{"name":"John Stagg","is_ca":true},{"name":"Roberto Salgado","is_ca":false},{"name":"Denis Larsimont","is_ca":false},{"name":"Christos Sotiriou","is_ca":false},{"name":"Françoise Rothé","is_ca":false},{"name":"Laurence Buisseret","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01088496838347184,"gpt":0.2894655851583049,"spread":0.2785806167748331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005150388,0.0001892903,0.0005384994,0.0004592156,0.0001076408,0.000003932537,0.0008210902,0.0004780738,0.0000267614],"category_scores_gemma":[0.0003569115,0.0001292997,0.0001994193,0.002761916,0.0006740897,0.000009326687,0.0003893306,0.0002626405,0.000001348646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005193928,"about_ca_system_score_gemma":0.0004107539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002754274,"about_ca_topic_score_gemma":0.0007689685,"domain_scores_codex":[0.9982057,0.0003572754,0.0005655828,0.0003806744,0.0001350781,0.0003556744],"domain_scores_gemma":[0.9984444,0.000165575,0.0004323607,0.000763283,0.0001703065,0.00002408156],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009796202,0.0007831251,0.04887722,0.00003701526,0.002946153,0.00002357048,0.001213922,0.02013448,0.8984324,0.002480408,0.001666195,0.01360925],"study_design_scores_gemma":[0.05365236,0.007444264,0.09192016,0.0001820885,0.003002756,0.00009388188,0.01719478,0.004916009,0.802582,0.004417554,0.01335726,0.001236889],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956042,0.001822821,0.00005254904,0.001343098,0.0004686481,0.0005329492,0.00005118234,0.00003792237,0.00008668476],"genre_scores_gemma":[0.9986267,0.0005652246,0.00007135405,0.00008569244,0.00006737309,0.0003906703,0.00004461814,0.0000208914,0.0001274776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09585046,"threshold_uncertainty_score":0.5272688,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389487916","doi":"10.1016/j.iotech.2023.100553","title":"81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"MD Precision (Canada)","funders":"Sanofi","keywords":"Docetaxel; Medicine; Internal medicine; Discontinuation; Oncology; Lung cancer; Chemotherapy; Confidence interval; Progression-free survival; Retrospective cohort study; Response Evaluation Criteria in Solid Tumors; Performance status; Progressive disease","authors":[{"name":"Marisa A. Bittoni","is_ca":false},{"name":"Sam Keeping","is_ca":true},{"name":"David P. Carbone","is_ca":false},{"name":"J.E. Park","is_ca":true},{"name":"A.T.H. Nguyen","is_ca":false},{"name":"K. Toor","is_ca":true},{"name":"Natalia Petruski‐Ivleva","is_ca":false},{"name":"A.K. Vadanahalli Shankar","is_ca":false},{"name":"Gerasimos Konidaris","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01099841336355249,"gpt":0.3132831200810172,"spread":0.3022847067174647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002954173,0.0004719746,0.0008412389,0.001404516,0.0001770375,0.00002542828,0.0003058378,0.0002470434,0.00003032391],"category_scores_gemma":[0.00002797375,0.0003045802,0.0000493675,0.00320585,0.0006971327,0.0001225045,0.00005945542,0.0005439477,0.000003944187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007924099,"about_ca_system_score_gemma":0.0006453821,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01148303,"about_ca_topic_score_gemma":0.01232193,"domain_scores_codex":[0.99751,0.0001293809,0.000681187,0.0006848605,0.0002299557,0.0007646753],"domain_scores_gemma":[0.9983439,0.0002396454,0.0003892499,0.0007387089,0.000201645,0.00008684519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002742772,0.002324447,0.9517009,0.0002284306,0.0003496647,0.0007916589,0.02867026,0.0008972511,0.008926983,0.00002888229,0.0001328912,0.003205829],"study_design_scores_gemma":[0.08155639,0.01747479,0.8104594,0.001488387,0.001188665,0.0001271089,0.02936551,0.009747943,0.04568284,0.00009173225,0.001634229,0.001183018],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938573,0.0004672282,0.00004156462,0.001831951,0.00005912309,0.003176507,0.00003237866,0.0002330648,0.0003009436],"genre_scores_gemma":[0.9941837,0.0006808302,0.001013962,0.0005424427,0.00001757502,0.002762724,0.0004575495,0.00008415386,0.0002570964],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1412416,"threshold_uncertainty_score":0.9999406,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310923924","doi":"10.1016/j.iotech.2022.100213","title":"109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Drug; Medicine; Pharmacology","authors":[{"name":"Brian H. Kushner","is_ca":false},{"name":"G.C. Chan","is_ca":false},{"name":"D.A. Morgenstern","is_ca":true},{"name":"L. Amoroso","is_ca":false},{"name":"K. Nysom","is_ca":false},{"name":"J. Faber","is_ca":false},{"name":"A. Wingerter","is_ca":false},{"name":"M. Bear","is_ca":false},{"name":"A. Rubio San Simon","is_ca":false},{"name":"K. Tornøe","is_ca":false},{"name":"P.S. Sørensen","is_ca":false},{"name":"J. Mora","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01469282178462866,"gpt":0.3674672308365919,"spread":0.3527744090519632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005428889,0.0002816277,0.0009294445,0.0008908773,0.0004046449,0.000005588815,0.0004237471,0.0002856142,0.001070353],"category_scores_gemma":[0.0002125634,0.0002302918,0.00020901,0.0008125411,0.001047656,0.00003938363,0.0008094407,0.001234154,0.0000394124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003619775,"about_ca_system_score_gemma":0.0005018655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002434608,"about_ca_topic_score_gemma":0.000006818613,"domain_scores_codex":[0.997735,0.0002037996,0.0005361369,0.0004857801,0.0004027914,0.0006364514],"domain_scores_gemma":[0.9985066,0.0004377074,0.0002077909,0.0006057084,0.000128656,0.0001135479],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01202606,0.003125018,0.1732513,0.0001424807,0.001367596,0.001291848,0.0005702575,0.00006478254,0.6996212,0.01207391,0.006488406,0.08997716],"study_design_scores_gemma":[0.01672738,0.03386168,0.6145012,0.0001389537,0.0002510625,0.007032992,0.001466549,0.0003039001,0.02884423,0.002175995,0.2939427,0.0007533955],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9809734,0.003052603,0.000007889607,0.009405547,0.000227428,0.0006074174,0.00009124161,0.0001480745,0.005486435],"genre_scores_gemma":[0.996873,0.001079869,0.0002923057,0.0002669987,0.00005306512,0.0000495478,0.00009205894,0.00003541534,0.001257744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.670777,"threshold_uncertainty_score":0.9998428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374842","doi":"10.1016/j.iotech.2024.100889","title":"5MO Novel radiologic phenotypes of chaotic tumor angiogenesis associated with poor ICI outcomes in NSCLC","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Syöpäsäätiö; Helsingin Yliopisto; Jane ja Aatos Erkon Säätiö; Ida Montinin Säätiö","keywords":"Angiogenesis; Phenotype; Chaotic; Medicine; Oncology; Internal medicine; Cancer research; Computer science; Biology; Genetics; Gene; Artificial intelligence","authors":[{"name":"Vamsidhar Velcheti","is_ca":false},{"name":"Rhea Chitalia","is_ca":false},{"name":"Carla Leibowitz","is_ca":false},{"name":"Kai Zhang","is_ca":true},{"name":"Anant Madabhushi","is_ca":false},{"name":"Nathaniel Braman","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01844260851793054,"gpt":0.274020598656686,"spread":0.2555779901387555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003446333,0.0003687989,0.001315052,0.001281118,0.00004565826,0.00000715046,0.0002914051,0.0006184911,0.00009912848],"category_scores_gemma":[0.0004168433,0.0002596845,0.0001959966,0.00133015,0.000691306,0.0000518478,0.0001326242,0.0004514211,0.00005007793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009314618,"about_ca_system_score_gemma":0.0004749702,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001363087,"about_ca_topic_score_gemma":0.0001712031,"domain_scores_codex":[0.9979125,0.00008839267,0.0006351176,0.0005691919,0.0001961396,0.0005987184],"domain_scores_gemma":[0.9985861,0.0004806094,0.0002036885,0.000544135,0.0001280964,0.00005743513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001193176,0.002710015,0.5336233,0.0002139427,0.003163102,0.005489861,0.0004465832,0.00003610703,0.4301256,0.004278411,0.0002652745,0.01845463],"study_design_scores_gemma":[0.01602091,0.01845795,0.7769913,0.001111322,0.002165845,0.004520182,0.001536937,0.0005291282,0.1721695,0.001703279,0.003832289,0.000961397],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820441,0.01034754,0.00009173504,0.004468973,0.000297847,0.0007948118,0.00002550827,0.0004770564,0.00145245],"genre_scores_gemma":[0.9971887,0.00008918233,0.001652027,0.0002453672,0.00002391178,0.0002106977,0.00003885971,0.00005833579,0.0004929058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2579561,"threshold_uncertainty_score":0.9999855,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374998","doi":"10.1016/j.iotech.2024.100749","title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology; Cancer","authors":[{"name":"Kristof Cuppens","is_ca":false},{"name":"G. Lo Russo","is_ca":false},{"name":"Óscar Juan","is_ca":false},{"name":"E. Felip","is_ca":false},{"name":"Ma Carmen Areses Manrique","is_ca":false},{"name":"Alberto Chiappori","is_ca":false},{"name":"E. Govaerts","is_ca":false},{"name":"P.K. Cheema","is_ca":true},{"name":"L. Greillier","is_ca":false},{"name":"L. Toschi","is_ca":false},{"name":"Eric Schaefer","is_ca":false},{"name":"M. Clouseau","is_ca":false},{"name":"C. Martinoli","is_ca":false},{"name":"Hussein Shehade","is_ca":false},{"name":"Natalie Byrne","is_ca":false},{"name":"M. Fox","is_ca":false},{"name":"M. Rossetti","is_ca":false},{"name":"Olivier De Henau","is_ca":false},{"name":"S. Ross","is_ca":false},{"name":"S. Peters","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01290091525342313,"gpt":0.2756339601567856,"spread":0.2627330449033625,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005615745,0.0005039791,0.001045341,0.0006208147,0.0001241115,0.00004506138,0.0004399226,0.0007923261,0.0001025197],"category_scores_gemma":[0.00009746202,0.0002588455,0.0001971115,0.001458822,0.001130561,0.00012976,0.0001108244,0.0009977422,0.000006869141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006580031,"about_ca_system_score_gemma":0.0008707513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001884403,"about_ca_topic_score_gemma":0.0001970915,"domain_scores_codex":[0.9968365,0.0001569704,0.001182762,0.0007612402,0.0004284193,0.0006341292],"domain_scores_gemma":[0.9979235,0.0003183671,0.0005233542,0.001075743,0.0001121243,0.00004694546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8010892,0.002104304,0.009345733,0.00005116398,0.000793136,0.0002048955,0.001579905,0.000001216713,0.02924704,0.00001316595,0.0001427378,0.1554275],"study_design_scores_gemma":[0.517886,0.0735526,0.1662041,0.006022595,0.0002726664,0.00009871741,0.001119951,0.00004715142,0.2101209,0.000132131,0.02364522,0.0008979644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850742,0.002128243,0.000005973027,0.007875944,0.001114964,0.003312292,0.00004588827,0.0002164441,0.0002260454],"genre_scores_gemma":[0.9978413,0.000255038,0.0003863491,0.0004567822,0.0001541559,0.0005922383,0.00004667071,0.0001026409,0.0001648122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2832031,"threshold_uncertainty_score":0.9999864,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117293508","doi":"10.1016/j.iotech.2025.101116","title":"33P High-dimensional spatial profiling of the tumor immune microenvironment (TIME) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) reveals predictive biomarkers of immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Head and neck squamous-cell carcinoma; Immunotherapy; Profiling (computer programming); Tumor microenvironment; Immune system; Head and neck; Basal cell; Head and neck cancer","authors":[{"name":"F. Peyraud","is_ca":false},{"name":"J-P. Guégan","is_ca":false},{"name":"A.B. Sudaka","is_ca":false},{"name":"N. Karpinich","is_ca":false},{"name":"J. Kim","is_ca":false},{"name":"R. Cheikh","is_ca":true},{"name":"S. Yadavilli","is_ca":false},{"name":"O. Lara","is_ca":false},{"name":"O. Odin","is_ca":false},{"name":"C. Pignon","is_ca":false},{"name":"C. Rey","is_ca":false},{"name":"E.B. Saada","is_ca":false},{"name":"S. Le Moulec","is_ca":false},{"name":"A. Bessede","is_ca":false},{"name":"A. Italiano","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00478656131430803,"gpt":0.2224617845606988,"spread":0.2176752232463908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003189528,0.0002798613,0.0005998795,0.0002859992,0.00008969318,0.000004260121,0.0004733526,0.0003775549,0.00001638694],"category_scores_gemma":[0.00008823703,0.0002418734,0.0001400987,0.0003217437,0.0009936988,0.000005592286,0.0003144176,0.0003072938,0.000001150986],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001113101,"about_ca_system_score_gemma":0.000265363,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003533364,"about_ca_topic_score_gemma":0.00008726293,"domain_scores_codex":[0.9980011,0.0002403989,0.0008073475,0.0004752544,0.0001123681,0.000363503],"domain_scores_gemma":[0.9988225,0.00007833631,0.0003989269,0.0005948484,0.00008173426,0.00002372307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001599998,0.0006191537,0.05147548,0.00008362105,0.0001243027,0.00000667226,0.0000655803,0.00004227885,0.9409029,0.00004544624,0.00004238055,0.00499214],"study_design_scores_gemma":[0.004929598,0.002129715,0.05535368,0.00009905583,0.00006996439,0.00003434631,0.0001387468,0.0001962157,0.9361458,0.0004103009,0.0003050264,0.0001875465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872382,0.01062679,0.0002707076,0.000433493,0.0004190778,0.0008044398,0.00007450235,0.00001485467,0.0001179752],"genre_scores_gemma":[0.9971957,0.0002313087,0.002226535,0.00009987778,0.00001321609,0.00007532045,0.00005033388,0.00002567952,0.00008202666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01039549,"threshold_uncertainty_score":0.9863311,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374515","doi":"10.1016/j.iotech.2024.100846","title":"103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Esophageal squamous cell carcinoma; Medicine; Chemoradiotherapy; Oncology; Basal cell; Multicenter study; Internal medicine; Carcinoma; Radiation therapy; Randomized controlled trial","authors":[{"name":"Zhihui Wen","is_ca":false},{"name":"Yuanyuan Song","is_ca":false},{"name":"Minghuan Li","is_ca":false},{"name":"Zhihong Liu","is_ca":false},{"name":"Yan Qu","is_ca":false},{"name":"Fengxia Hao","is_ca":false},{"name":"Jiajia Liu","is_ca":false},{"name":"Beilei Xu","is_ca":false},{"name":"Xueying Yu","is_ca":false},{"name":"Sheng Chen","is_ca":false},{"name":"Xiaochang Wu","is_ca":false},{"name":"Guang Cheng","is_ca":false},{"name":"Huijun Lu","is_ca":false},{"name":"Xiaolei Zhang","is_ca":false},{"name":"H. Wang","is_ca":false},{"name":"Yuqiang Cheng","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01325214264849089,"gpt":0.3187447232035502,"spread":0.3054925805550593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000250672,0.000549728,0.001168913,0.0009652112,0.0002315292,0.00004861141,0.0004017676,0.0003753493,0.0001376611],"category_scores_gemma":[0.0000666898,0.000433639,0.0001773684,0.001213048,0.0005407872,0.0001305988,0.0001408567,0.0007974249,0.00004699334],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002587087,"about_ca_system_score_gemma":0.001024273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002000387,"about_ca_topic_score_gemma":0.001066032,"domain_scores_codex":[0.9967908,0.00009589785,0.000578442,0.001127411,0.0003554136,0.001052063],"domain_scores_gemma":[0.9980689,0.0003417185,0.0001512909,0.0008940083,0.000353808,0.00019029],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1410411,0.08129874,0.3927483,0.002537004,0.003880693,0.04629888,0.005213611,0.0000499052,0.07024034,0.004928799,0.003965833,0.2477968],"study_design_scores_gemma":[0.1941916,0.5061646,0.04333467,0.0003235662,0.001535122,0.00142534,0.003389489,0.001250678,0.23366,0.001621031,0.01175862,0.001345257],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.960015,0.02079327,0.0005894751,0.00320083,0.0005201948,0.01006139,0.00004949019,0.001313261,0.003457103],"genre_scores_gemma":[0.9867777,0.0001330419,0.004927418,0.000150801,0.0001097801,0.00401407,0.00005846992,0.0001524345,0.003676338],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4248658,"threshold_uncertainty_score":0.9998115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374417","doi":"10.1016/j.iotech.2024.100929","title":"176MO ORCA-010 oncolytic therapy: Inducing tumor-specific immune responses and activation of tumor microenvironment in treatment-naïve prostate cancer","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Joseph’s Healthcare Hamilton; Oakville-Trafalgar Memorial Hospital; Joseph Brant Hospital; The Scarborough Hospital; Brampton Civic Hospital","funders":"Novo Nordisk; National Institute for Health and Care Research; H. Lundbeck A/S; Cancer Research UK; Gordon and Rose McAlpine Foundation for Neuroscience Research; Francis Crick Institute","keywords":"Prostate cancer; Oncolytic virus; Immune system; Tumor microenvironment; Cancer; Medicine; Cancer research; Oncology; Immune escape; Internal medicine; Immunology","authors":[{"name":"T.D. de Gruijl","is_ca":false},{"name":"Reza Nadafi","is_ca":false},{"name":"T. Brachtlová","is_ca":false},{"name":"Jonathan Giddens","is_ca":true},{"name":"Kenneth Jansz","is_ca":true},{"name":"Peter Incze","is_ca":true},{"name":"Amitai Abramovitch","is_ca":true},{"name":"B. Shayegan","is_ca":true},{"name":"Richard Casey","is_ca":true},{"name":"Wanli Dong","is_ca":false},{"name":"Victor W. van Beusechem","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01479310649360675,"gpt":0.3085348285810627,"spread":0.2937417220874559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001862714,0.000264257,0.0003854989,0.0004596502,0.00007829697,0.0000213402,0.0001880385,0.0002620489,0.00005375691],"category_scores_gemma":[0.00003538314,0.0002298618,0.00007437471,0.0003563932,0.0005037257,0.00001421955,0.0001684022,0.0002385711,0.000007628032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006350606,"about_ca_system_score_gemma":0.0005769957,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008579937,"about_ca_topic_score_gemma":0.0002950726,"domain_scores_codex":[0.9983746,0.0001211052,0.0003901204,0.000583562,0.0001008885,0.0004296886],"domain_scores_gemma":[0.9993002,0.00006536365,0.0001277439,0.0004257954,0.00003703775,0.00004383552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001627755,0.000293543,0.00702471,0.00002168607,0.0002769924,0.0001299589,0.0002485921,0.000007298812,0.8657309,0.00004316417,0.0001121856,0.1244833],"study_design_scores_gemma":[0.002905896,0.00388393,0.009470802,0.0001050185,0.00001796519,0.000134057,0.0004386731,0.00001328557,0.8992495,0.0001864274,0.08339626,0.0001982079],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.934634,0.06303194,0.000009093812,0.001200781,0.0001364503,0.000744309,0.00006502706,0.00003946371,0.0001389004],"genre_scores_gemma":[0.9772958,0.02132801,0.0001784722,0.00005067065,0.00004251477,0.0006999845,0.00005677731,0.0000405143,0.0003072982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.124285,"threshold_uncertainty_score":0.9373494,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374727","doi":"10.1016/j.iotech.2024.100823","title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Loxo Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; PharmaMar; Basilea Pharmaceutica; Astellas Pharma; Eisai; Eisai Canada; BeiGene; Relay Therapeutics; Seagen; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boston Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; Daiichi Sankyo Europe; Servier; Foghorn Therapeutics; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Association (psychology); Internal medicine; Medicine; Oncology; Psychology; Psychotherapist","authors":[{"name":"Constance d’Abrigeon","is_ca":false},{"name":"Kaïssa Ouali","is_ca":false},{"name":"Noé Herbel","is_ca":false},{"name":"Stéphane Champiat","is_ca":false},{"name":"Antoine Hollebecque","is_ca":false},{"name":"C. Smolenschi","is_ca":false},{"name":"Madona Sakkal","is_ca":false},{"name":"Ratislav Bahleda","is_ca":false},{"name":"Anas Gazzah","is_ca":false},{"name":"Anna Patrikidou","is_ca":false},{"name":"Jean‐Marie Michot","is_ca":false},{"name":"Thomas Hueso","is_ca":false},{"name":"S. Ammari","is_ca":false},{"name":"Y. Loriot","is_ca":false},{"name":"C. Massard","is_ca":false},{"name":"A. Bernard-Tessier","is_ca":false},{"name":"M. Texier","is_ca":false},{"name":"C. Baldini","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007270466107637963,"gpt":0.2744945569153401,"spread":0.2672240908077022,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001393329,0.0002150961,0.0005917113,0.0007368774,0.00009162538,0.000009045731,0.00008792484,0.0005401892,0.00002210256],"category_scores_gemma":[0.001260793,0.0001448936,0.00002789997,0.000877681,0.0009669994,0.00005701982,0.00006002202,0.0008340392,0.00002417855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009091359,"about_ca_system_score_gemma":0.0003271144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006195607,"about_ca_topic_score_gemma":0.00005134709,"domain_scores_codex":[0.9982425,0.0004140724,0.0002811759,0.000477032,0.0001346744,0.0004505662],"domain_scores_gemma":[0.9985077,0.001002735,0.00009834795,0.0002480658,0.00009084454,0.00005228382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01022468,0.0001833625,0.9371952,0.0001038736,0.0004830075,0.006357185,0.0003118647,0.000002955378,0.03414201,0.0004980135,0.00186253,0.00863531],"study_design_scores_gemma":[0.008608952,0.0130009,0.936004,0.001043322,0.000587736,0.01327174,0.002496434,0.0004691736,0.002014076,0.001021896,0.02103636,0.000445427],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9705589,0.007492715,0.0001657669,0.01959445,0.000157129,0.0004175558,0.000004627851,0.0005341413,0.001074756],"genre_scores_gemma":[0.9971367,0.0002732234,0.001307261,0.0003187697,0.00002525676,0.0001615801,0.00001087199,0.00002260521,0.000743727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03212793,"threshold_uncertainty_score":0.5908591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117315492","doi":"10.1016/j.iotech.2025.101210","title":"126P Neoadjuvant (neoadj) nivolumab (N) + chemotherapy (C) in patients (pts) with resectable NSCLC: Outcomes by subsequent immunotherapy (IO) in CheckMate 816","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Trinity College; McGill University Health Centre","funders":"","keywords":"Nivolumab; Chemotherapy; Immunotherapy; Chemoimmunotherapy; Neoadjuvant therapy; MEDLINE","authors":[{"name":"N. Girard","is_ca":false},{"name":"S. Lucherini","is_ca":false},{"name":"M. Provencio Pulla","is_ca":false},{"name":"M. Awad","is_ca":false},{"name":"J. Spicer","is_ca":true},{"name":"T. Mitsudomi","is_ca":false},{"name":"C. Wang","is_ca":false},{"name":"S. Lu","is_ca":false},{"name":"E. Felip","is_ca":false},{"name":"J.R. Brahmer","is_ca":false},{"name":"S. Broderick","is_ca":false},{"name":"T-E. Ciuleanu","is_ca":false},{"name":"F. Tanaka","is_ca":false},{"name":"G. Saylors","is_ca":false},{"name":"L. Lupinacci","is_ca":false},{"name":"S. Bhatia","is_ca":false},{"name":"J.L. Cai","is_ca":false},{"name":"N. Hu","is_ca":false},{"name":"P.M. Forde","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005142110023032019,"gpt":0.2744393243525463,"spread":0.2692972143295143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006362041,0.0006524675,0.001628944,0.001832936,0.0001513141,0.00003158068,0.0007561306,0.001263267,0.0003616773],"category_scores_gemma":[0.00008671473,0.000547574,0.0002027672,0.002414639,0.0009075335,0.0001822791,0.0001491366,0.001152402,0.00002968559],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002624397,"about_ca_system_score_gemma":0.000840112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001845771,"about_ca_topic_score_gemma":0.001368285,"domain_scores_codex":[0.9959831,0.0001820645,0.001284869,0.0009575203,0.0003413816,0.001251084],"domain_scores_gemma":[0.997905,0.000154287,0.0003798165,0.001294752,0.0001999978,0.00006611829],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02394617,0.003122571,0.6367442,0.00007176663,0.0008299974,0.0001474177,0.0005202562,0.00000338154,0.09507343,0.0002853609,0.003706102,0.2355493],"study_design_scores_gemma":[0.1333524,0.009217094,0.5455231,0.001061528,0.0001036774,0.0001298674,0.001407103,0.00005318451,0.06184969,0.001086521,0.2449726,0.001243209],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9672557,0.009640004,0.00007240554,0.01635711,0.0005704908,0.002056646,0.0000229606,0.0003527425,0.003671986],"genre_scores_gemma":[0.9877149,0.003116033,0.0006478516,0.004390386,0.0000164528,0.0006706323,0.00008823151,0.0001065453,0.003248896],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2412665,"threshold_uncertainty_score":0.9996976,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117298964","doi":"10.1016/j.iotech.2025.101461","title":"262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Cancer Society; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Placebo; Adjuvant; Mutation; Clinical trial","authors":[{"name":"T. Mimae","is_ca":false},{"name":"G. Goss","is_ca":true},{"name":"G. Darling","is_ca":true},{"name":"V. Westeel","is_ca":false},{"name":"K. Nakagawa","is_ca":false},{"name":"B. Massuti Sureda","is_ca":false},{"name":"F. Perrone","is_ca":false},{"name":"S-A. McLachlan","is_ca":false},{"name":"J.H. Kang","is_ca":false},{"name":"Y-L. Wu","is_ca":false},{"name":"A-M.C. Dingemans","is_ca":false},{"name":"R. Dziadziuszko","is_ca":false},{"name":"M. Okada","is_ca":false},{"name":"L. Greillier","is_ca":false},{"name":"C. Audigier-Valette","is_ca":false},{"name":"S. Sugawara","is_ca":false},{"name":"E. Nadal","is_ca":false},{"name":"M.R. Stockler","is_ca":false},{"name":"Ku Ke Ding","is_ca":true},{"name":"C. O'Callaghan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01786102216622019,"gpt":0.3937564791857949,"spread":0.3758954570195747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004434023,0.0002222339,0.0006725526,0.0008481463,0.0001651732,0.000009509838,0.0004070332,0.0004916962,0.0002302731],"category_scores_gemma":[0.0006489678,0.0001506634,0.0001215931,0.001288305,0.0005704977,0.00006714294,0.0001164721,0.0004446645,0.00003594239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006202758,"about_ca_system_score_gemma":0.001132924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003597279,"about_ca_topic_score_gemma":0.0008505776,"domain_scores_codex":[0.9981196,0.000191279,0.0007219705,0.0003707593,0.0001961415,0.0004002683],"domain_scores_gemma":[0.9982532,0.0005526741,0.0002414773,0.0007608936,0.0001625459,0.00002920036],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1296142,0.01513259,0.02178989,0.0004641286,0.006047468,0.001825454,0.01256714,0.00006977289,0.03764157,0.04771216,0.0333566,0.693779],"study_design_scores_gemma":[0.3642858,0.01265736,0.01544963,0.0005170032,0.002866842,0.0005378767,0.02393909,0.0001035293,0.0073483,0.009187351,0.5626138,0.000493369],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8606147,0.002662805,0.0003075606,0.05210539,0.002051724,0.005007078,0.00006607618,0.0002844795,0.07690024],"genre_scores_gemma":[0.9926136,0.000381049,0.001600665,0.0008031616,0.00005316673,0.001367572,0.0000981218,0.00002197054,0.003060733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6932856,"threshold_uncertainty_score":0.6143876,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","authors":[{"name":"R.S. Tan","is_ca":true},{"name":"N. Sereesongsaeng","is_ca":true},{"name":"R. D'Souza","is_ca":true},{"name":"A. Furness","is_ca":false},{"name":"T. Rabbitts","is_ca":true},{"name":"A. Klampatsa","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01653322237313259,"gpt":0.3857095453749428,"spread":0.3691763230018102,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001262159,0.0002573978,0.0009825905,0.001466963,0.0000932394,0.00000834717,0.0005475813,0.0008927116,0.0003437459],"category_scores_gemma":[0.0001625126,0.0002458367,0.000169353,0.001086934,0.0005264028,0.00006296124,0.0001828289,0.0008109734,0.00000374628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007116895,"about_ca_system_score_gemma":0.001156361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001524601,"about_ca_topic_score_gemma":0.00005042448,"domain_scores_codex":[0.9975818,0.0002060602,0.0007450049,0.0005525969,0.0001938994,0.0007206775],"domain_scores_gemma":[0.9980789,0.0005017607,0.000204724,0.0008498998,0.0003096744,0.00005508411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001783348,0.000953573,0.005370138,0.0000738544,0.0001247363,0.00004096306,0.0001134443,0.000003561635,0.7697393,0.0005585441,0.0002367733,0.2210018],"study_design_scores_gemma":[0.01288854,0.003701256,0.002928002,0.0000534191,0.00004696208,0.00003914337,0.001445802,0.0009599181,0.892676,0.001957437,0.08310503,0.0001984887],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9767666,0.003793592,0.0009232793,0.004872318,0.0004676846,0.002218661,0.00001589256,0.0002035322,0.01073838],"genre_scores_gemma":[0.9826821,0.0007099387,0.0136064,0.0004270963,0.00005784809,0.0007128812,0.0000701089,0.0000475556,0.001686057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2208033,"threshold_uncertainty_score":0.9999994,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}